Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Helperby Therapeutics Limited currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner and 1 distinct art unit. This reflects a very focused prosecution profile where all active matters are handled by a single individual in one administrative division, showing no fragmentation of legal efforts.
The busiest examiner for the portfolio is HIRAKIS, SOPHIA P, who is responsible for 1 pending office action. Since the total number of pending actions is 1, this examiner manages the entirety of the company's current active cases. This 1 to 1 ratio between the busiest examiner's workload and the total portfolio activity highlights the centralized nature of the prosecution. The outcome depends on the specific interpretations of HIRAKIS, SOPHIA P.
The presence of 1 distinct art unit indicates a specific technical focus for the current filings in the Biotechnology & Pharmaceuticals field. Practitioners should be aware that the 1 pending office action is not distributed among multiple examiners. This concentration means there are no alternative examiner perspectives to draw from within the current workload, making the interaction with the assigned official critical.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 1 | 57.4% | +69.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641257 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | HIRAKIS, SOPHIA P | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17641257 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | HIRAKIS, SOPHIA P | 1623 | §103DP | Final Rejection | 49d overdue | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHelperby Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sophia P Hirakis has the most, with 1 of Helperby Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
